MedPath

Almonertinib

Generic Name
Almonertinib
Drug Type
Small Molecule
Chemical Formula
C30H35N7O2
CAS Number
1899921-05-1
Unique Ingredient Identifier
T4RS462G19
Background

Almonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations. It is being investigated against advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC).

Indication

1.用于既往经表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）治疗时或治疗后出现疾病进展，并且经检测确认存在EGFR T790M 突变阳性的局部晚期或转移性非小细胞肺癌成人患者的治疗。

2.用于表皮生长因子受体（EGFR）敏感突变阳性局部晚期或转移性非小细胞肺癌（NSCLC）患者一线治疗。

Clinical Trials
Related News

Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer

Phase 2
Active, not recruiting
Conditions
Non-small Cell Lung Cancer Stage III
Interventions
First Posted Date
2020-12-28
Last Posted Date
2024-08-14
Lead Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Target Recruit Count
56
Registration Number
NCT04685070
Locations
🇨🇳

Shanghai Pulmonary Hospital, Shanghai, Shanghai, China

Almonertinib With Chemotherapy in mEGFR NSCLC

Phase 2
Conditions
Non-Small Cell Lung Cancer Metastatic
Interventions
First Posted Date
2020-11-30
Last Posted Date
2020-12-02
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
10
Registration Number
NCT04646824
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases

Phase 2
Conditions
EGFR Positive Non-small Cell Lung Cancer
Brain Metastases
Interventions
First Posted Date
2020-11-25
Last Posted Date
2020-11-25
Lead Sponsor
First People's Hospital of Hangzhou
Target Recruit Count
47
Registration Number
NCT04643847
Locations
🇨🇳

Hangzhou Cancer Hospital, Hangzhou, Zhejiang, China

A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC

Phase 2
Conditions
Non Small Cell Lung Cancer
Stage III NSCLC
EGFR Activating Mutation
Interventions
First Posted Date
2020-11-19
Last Posted Date
2021-01-12
Lead Sponsor
First People's Hospital of Hangzhou
Target Recruit Count
43
Registration Number
NCT04636593
Locations
🇨🇳

Hangzhou Cancer hospital, Hangzhou, Zhejiang, China

Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer

Phase 2
Conditions
Lung Cancer, Non-small Cell
EGFR T790M
EGFR Gene Mutation
Interventions
First Posted Date
2020-10-19
Last Posted Date
2020-10-19
Lead Sponsor
Fudan University
Target Recruit Count
226
Registration Number
NCT04592666
Locations
🇨🇳

Cancer hospital Fudan University, Shanghai, Shanghai, China

Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial

Phase 2
Conditions
Non Small Cell Lung Cancer
Interventions
First Posted Date
2020-09-18
Last Posted Date
2020-10-14
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
53
Registration Number
NCT04553887
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation

Phase 3
Conditions
Non Small Cell Lung Cancer
Interventions
First Posted Date
2020-08-05
Last Posted Date
2020-08-05
Lead Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Target Recruit Count
460
Registration Number
NCT04500717
Locations
🇨🇳

Beijing Chest Hospital, Capital Medical University, Beijing, China

🇨🇳

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China

🇨🇳

Peking University International Hospital, Beijing, China

and more 2 locations

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC

Phase 3
Conditions
Non Small Cell Lung Cancer
Interventions
First Posted Date
2020-08-05
Last Posted Date
2020-08-05
Lead Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Target Recruit Count
166
Registration Number
NCT04500704
Locations
🇨🇳

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

🇨🇳

Beijing Chest Hospital, Capital Medical University, Beijing, China

🇨🇳

Tianjin Medical University Cancer Institute & Hospital, Tianjin, China

and more 2 locations

Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC

Phase 2
Not yet recruiting
Conditions
Non-Small Cell Lung Cancer Stage IIIA
Interventions
First Posted Date
2020-07-02
Last Posted Date
2020-07-02
Lead Sponsor
The First Affiliated Hospital of Guangzhou Medical University
Target Recruit Count
168
Registration Number
NCT04455594
Locations
🇨🇳

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

PLATFORM Study of Precision Medicine for Rare Tumors

First Posted Date
2020-06-09
Last Posted Date
2025-02-11
Lead Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Target Recruit Count
770
Registration Number
NCT04423185
Locations
🇨🇳

Cancer hospital Chinese Academy of Medical Sciences, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy